New drug duo aims to tame tough blood disorder
NCT ID NCT07424950
Summary
This study is testing whether adding a new drug called bomedemstat to an existing drug (momelotinib) can better control myelofibrosis, a serious bone marrow disease. It is for patients who have not had an optimal response to momelotinib alone. About 40 participants will take momelotinib for 12 weeks, then add bomedemstat for another 12 weeks to see if the combination improves their condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.